SCHEMBL5042256

SCHEMBL5042256

Cc1cccc(Oc2cnc(N)nc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.61
▸ LYN P07948 1/20 0.56
▸ GAA P10253 1/20 0.53
▸ CDK8 P49336 2/20 0.49
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ ACHE P22303 2/20 0.47
▸ MAP4K4 O95819 1/20 0.47
▸ MAPT P10636 2/20 0.47
▸ LMNA P02545 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.45
▸ EGFR P00533 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ BCHE P06276 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tolimidone SCHEMBL21168610 0.82 LYN (0.56) ALDH1A1LYNGAACDK8MEN1
SCHEMBL456868 0.80 ALDH1A1 (0.72) ALDH1A1LYNGAAMEN1KMT2A
SCHEMBL29746015 0.80 ALDH1A1 (0.72) ALDH1A1LYNGAAMEN1KMT2A
SCHEMBL29398372 0.80 ALDH1A1 (0.72) ALDH1A1LYNGAAMEN1KMT2A
SCHEMBL5042253 0.79 LYN (0.54) ALDH1A1LYNGAACDK8MEN1
SCHEMBL8736450 0.79 LYN (0.60) ALDH1A1LYNGAACDK8MEN1
SCHEMBL6470759 0.78 CYP3A4 (0.49) ALDH1A1GAACDK8MEN1KMT2A
SCHEMBL1688852 0.78 ALDH1A1 (0.69) ALDH1A1LYNGAAMEN1KMT2A
SCHEMBL29377828 0.78 ALDH1A1 (0.69) ALDH1A1LYNGAAMEN1KMT2A
SCHEMBL29851471 0.78 ALDH1A1 (0.55) ALDH1A1LYNGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 — — US claimed
EP-1654260-A4 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PROD INC (US) 2008-09-24 — — EP disclosed
EP-1654260-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2006-05-10 — — EP disclosed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 — — US disclosed
WO-2005011601-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS, INC. (US) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA ALDH1A1 2820/4885LYN 2405/4885GAA 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback